Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-46 PET in Crohn's Disease Patients
NCT07273188Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga FAPI-46 in Crohn's disease, sponsored by Mayo Clinic. Primary endpoints: Completion of PET/CT with Ga68-FAPI-46 by all participants at 2 years and Number of participants completing PET/CT with Ga68-FAPI-46 at 2 years. Started Jan 2026; status: recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07273188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273188.